Cereno Scientific looks to enter PAH market with its leading product CS-1

23 April 2020 (Last Updated April 23rd, 2020 09:27)

In March, the US Food and Drug Administration (FDA) granted Cereno Scientific’s preclinical candidate CS-1 (valproic acid) Orphan Drug Designation for pulmonary arterial hypertension.

GlobalData supposes that CS-1 could fill a gap in the market due to its innovative mechanism of action, particularly epigenetic modulation of cardiovascular disease by histone deacetylase inhibition.